Longboard Pharmaceuticals, Inc. — Cyborg Score 7/10
Strong
Rare neurological disease therapeutics
Strategic Profile
Longboard was founded in 2020 based on assets spun out from Arena Pharmaceuticals after it was acquired for $6.7 billion by Pfizer. Lundbeck finalized acquisition in December 2024 for $2.6 billion; the company had about 50 full-time employees at the time and believes Longboard's lead asset has potential to become a blockbuster product helping treat patients with Dravet syndrome and Lennox-Gastaut syndrome among other rare epilepsies.
Cyborg Score Rationale
Longboard's lead product Bexicaserin is expected to launch in 2028 with peak global sales projected between $1.5 billion and $2 billion. The FDA granted breakthrough designation, which helped increase the acquisition offer price. The acquisition by major pharma (Lundbeck) validates the clinical potential and commercialization pathway.
Top Insights
Second-largest biotech acquisition on record in 2024 behind only Rayzebio, validating strong clinical and commercial potential
Targeting patients with over 20 types of rare brain disorders affecting roughly 220,000 people in the U.S., half of which lack effective treatment options with few side effects
Leverages over 20 years of GPCR research from Arena Pharmaceuticals, representing decades of drug development and optimization experience
Longboard now operates as Lundbeck subsidiary, gaining access to global pharma infrastructure and commercial capabilities for rare disease development
Named Competitors
Epidiolex — CBD for seizures in Dravet and Lennox-Gastaut syndromes
Fintepla — Fenfluramine for rare developmental and epileptic encephalopathies
Neuraxpharm products — Ganaxolone and other neurological therapeutics
Recent Developments
(December 2024) Lundbeck completed acquisition of Longboard for $2.6 billion; company became wholly owned subsidiary
(2024) FDA granted breakthrough designation for lead asset bexicaserin
(2023) Positive update on PACIFIC Study showing seizure reductions in DEE patients
Open the full interactive Longboard Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.